Plau-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Plau-KO 基因敲除小鼠

产品编号

S-KO-03697

品系全称

C57BL/6NCya-Plauem1/Cya

品系背景

C57BL/6NCya

品系编号

KOCMP-18792-Plau-B6N-VA

品系状态

使用本品系发表的文献需注明: Plau-KO 基因敲除小鼠 mice (Strain S-KO-03697) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量
KO小鼠库模型
NF-κB信号通路

基本信息

基因研究概述

质控标准

基因
基因全称
plasminogen activator, urokinase
基因别称
u-PA,uPA
染色体号
Chr 14 (Mouse)
转录本 ID
NCBI: NM_008873 | Ensembl: ENSMUST00000022368
修饰方式
全身性基因敲除
靶向范围
Exon 1~11
敲除长度
~6.7 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:97611Homozygotes show occasional fibrin deposits in non-healing ulcerations and reduced neointima formation after arterial injury. They are susceptible to thrombosis after traumatic or inflammatory challenge and appear to be immunologically hyporesponsive displaying characteristics of functional anergy.
PLAU,即尿激酶型纤溶酶原激活剂(Urokinase-type plasminogen activator),是一种重要的丝氨酸蛋白酶,在多种生理和病理过程中发挥关键作用。PLAU负责将无活性的纤溶酶原转化为有活性的纤溶酶,后者可以降解细胞外基质成分,如纤维蛋白、胶原蛋白和层粘连蛋白等,从而促进细胞迁移、血管生成和细胞增殖。PLAU的表达和活性受到多种因素的调控,包括基因表达、转录后修饰和蛋白质翻译等。

PLAU在多种肿瘤的发生和发展中发挥重要作用。例如,PLAU在甲状腺癌中的表达与患者的复发风险相关,高表达的PLAU与患者的不良预后相关[1]。PLAU还与胶质瘤的发生和发展相关,高表达的PLAU和其受体PLAUR与患者的生存期缩短相关[2]。此外,PLAU还与主动脉瘤的发生和发展相关,抑制PLAU的表达可以降低主动脉瘤的风险[3]。PLAU还与Sjögren's综合征的发生和发展相关,PLAU的表达与该疾病的严重程度相关[4]。PLAU还与Wilms瘤的发生和发展相关,低表达的PLAU与患者的不良预后相关[5]。PLAU还与皮肤瘢痕的形成相关,抑制PLAU的表达可以改善瘢痕的质量[6]。PLAU还与肺鳞状细胞癌的发生和发展相关,PLAU的表达与患者的不良预后相关[7]。PLAU还与胃癌的发生和发展相关,PLAU和FOXM1的表达与患者的不良预后相关[8]。PLAU还与非小细胞肺癌的发生和发展相关,PLAU的表达与患者的不良预后相关[9]。PLAU还与胆管癌的发生和发展相关,PLAU的表达与患者的不良预后相关[10]。

综上所述,PLAU是一种重要的丝氨酸蛋白酶,在多种生理和病理过程中发挥关键作用。PLAU在多种肿瘤的发生和发展中发挥重要作用,可以作为肿瘤诊断和治疗的潜在靶点。

参考文献:
1. Wu, Min, Wei, Bo, Duan, Sai-Li, Huang, Peng, Chang, Shi. 2022. Methylation-Driven Gene PLAU as a Potential Prognostic Marker for Differential Thyroid Carcinoma. In Frontiers in cell and developmental biology, 10, 819484. doi:10.3389/fcell.2022.819484. https://pubmed.ncbi.nlm.nih.gov/35141223/
2. Li, Junhong, Fan, Huanhuan, Zhou, Xingwang, Xiang, Yufan, Liu, Yanhui. 2022. Prognostic Significance and Gene Co-Expression Network of PLAU and PLAUR in Gliomas. In Frontiers in oncology, 11, 602321. doi:10.3389/fonc.2021.602321. https://pubmed.ncbi.nlm.nih.gov/35087738/
3. Chen, Yanghui, Xu, Xin, Wang, Linlin, Wang, Yan, Wang, Dao Wen. 2022. Genetic insights into therapeutic targets for aortic aneurysms: A Mendelian randomization study. In EBioMedicine, 83, 104199. doi:10.1016/j.ebiom.2022.104199. https://pubmed.ncbi.nlm.nih.gov/35952493/
4. Bai, Yingjie, Wang, Jiayi, Feng, Xuefeng, Ma, Guowu, Zhang, Fan. 2024. Identification of drug targets for Sjögren's syndrome: multi-omics Mendelian randomization and colocalization analyses. In Frontiers in immunology, 15, 1419363. doi:10.3389/fimmu.2024.1419363. https://pubmed.ncbi.nlm.nih.gov/38933282/
5. Li, Ding, Ding, Chen, Huang, Fan, Gao, Hongjie, Sun, Fengyin. . Bioinformatics Analysis of the Expression and Prognostic Value of PLAU Gene in Wilms' Tumor. In Anticancer research, 44, 3829-3842. doi:10.21873/anticanres.17209. https://pubmed.ncbi.nlm.nih.gov/39197889/
6. Vorstandlechner, Vera, Laggner, Maria, Copic, Dragan, Ankersmit, Hendrik Jan, Mildner, Michael. 2021. The serine proteases dipeptidyl-peptidase 4 and urokinase are key molecules in human and mouse scar formation. In Nature communications, 12, 6242. doi:10.1038/s41467-021-26495-2. https://pubmed.ncbi.nlm.nih.gov/34716325/
7. Guo, Jiankun, Wang, Hailong, Huang, Changhua, Luo, Shiwen, Chen, Limin. 2024. PLAU, transcriptionally negatively regulated by GATA6, promotes lung squamous carcinoma cell proliferation and migration. In Biochimica et biophysica acta. Molecular cell research, 1871, 119744. doi:10.1016/j.bbamcr.2024.119744. https://pubmed.ncbi.nlm.nih.gov/38702016/
8. Ai, Chao, Zhang, Jixin, Lian, Shenyi, Han, Yong, Feng, Qin. 2020. FOXM1 functions collaboratively with PLAU to promote gastric cancer progression. In Journal of Cancer, 11, 788-794. doi:10.7150/jca.37323. https://pubmed.ncbi.nlm.nih.gov/31949481/
9. Zheng, Yuanliang, Zhang, Lixiang, Zhang, Kangliang, Huang, Risheng, Liao, Hongli. 2024. PLAU promotes growth and attenuates cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1. In Biology direct, 19, 7. doi:10.1186/s13062-024-00452-7. https://pubmed.ncbi.nlm.nih.gov/38229120/
10. Hu, Mei-Di, Jia, Ling-Hua, Wang, Ming-Long. 2023. PLAU contributes to the development of cholangiocarcinoma via activating NF-κB signaling pathway. In Cell biology international, 47, 1381-1391. doi:10.1002/cbin.12025. https://pubmed.ncbi.nlm.nih.gov/37067236/